[HTML][HTML] Platinum-based chemotherapy plus cetuximab in head and neck cancer
JB Vermorken, R Mesia, F Rivera… - … England Journal of …, 2008 - Mass Medical Soc
Background Cetuximab is effective in platinum-resistant recurrent or metastatic squamous-
cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus …
cell carcinoma of the head and neck. We investigated the efficacy of cetuximab plus …
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head …
J Bourhis, F Rivera, R Mesia, A Awada… - Journal of clinical …, 2006 - ascopubs.org
Purpose This was an open, randomized, multicenter, phase I/II study to investigate the safety
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …
and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell …
Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum‐based …
BACKGROUND. The epidermal growth factor receptor (EGFR) inhibitor cetuximab is active
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …
in recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). The …
[HTML][HTML] A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic …
P Bossi, R Miceli, LD Locati, D Ferrari, S Vecchio… - Annals of …, 2017 - Elsevier
Abstract Background B490 (EudraCT# 2011-002564-24) is a randomized, phase 2b,
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …
noninferiority study investigating the efficacy and safety of first-line cetuximab plus cisplatin …
[HTML][HTML] Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter …
J Guigay, J Fayette, AF Dillies, C Sire, JN Kerger… - Annals of …, 2015 - Elsevier
Background Cetuximab in combination with platinum and 5-fluorouracil is the standard of
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …
care in the first-line treatment of patients with recurrent/metastatic head and neck squamous …
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic …
JB Vermorken, J Trigo, R Hitt, P Koralewski… - Journal of clinical …, 2007 - ascopubs.org
Purpose To evaluate the efficacy and safety of the epidermal growth factor receptor–directed
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …
monoclonal antibody cetuximab administered as a single agent in patients with recurrent …
Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a …
J Trigo, R Hitt, P Koralewski, E Diaz-Rubio… - Journal of Clinical …, 2004 - ascopubs.org
5502 Background: Pts with refractory SCCHN have a poor prognosis with few therapeutic
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …
options. Cetuximab (Erbitux), an IgG1 monoclonal antibody that binds selectively to EGFR …
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients …
J Baselga, JM Trigo, J Bourhis, J Tortochaux… - Journal of clinical …, 2005 - ascopubs.org
Purpose To evaluate the efficacy and safety of the antiepidermal growth factor receptor
monoclonal antibody cetuximab in combination with platinum-based chemotherapy in …
monoclonal antibody cetuximab in combination with platinum-based chemotherapy in …
[HTML][HTML] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell …
R Hitt, A Irigoyen, H Cortes-Funes, JJ Grau… - Annals of …, 2012 - Elsevier
Background The efficacy and safety of a novel combination of weekly paclitaxel and the
epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line …
epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab for the first-line …
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative …
B Burtness, MA Goldwasser, W Flood… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Therapy of recurrent/metastatic squamous cell carcinoma of the head and neck
results in median progression-free survival (PFS) of 2 months. These cancers are rich in …
results in median progression-free survival (PFS) of 2 months. These cancers are rich in …
相关搜索
- head and neck cell carcinoma
- neck cancer cetuximab in head
- neck in patients efficacy of cetuximab
- head and neck fluorouracil in patients
- head and neck combination with cisplatin
- head and neck weekly paclitaxel
- head and neck efficacy of cetuximab
- head and neck combination of cetuximab
- head and neck cetuximab monotherapy
- head and neck patients pts